Зеденолейцел

Rec. INN (наименование, зарегистрированное ВОЗ)

allogeneic multi-tumour associated antigen specific T lymphocytes prepared from peripheral blood mononuclear cells (PBMCs), collected by apheresis from human leukocyte antigen (HLA)-matched donors. The donor T cells are purified by depleting CD14+ and CD56+ cells, then co-cultured ex vivo with antigen presenting dendritic cells, derived from the same donor that have been exposed to a peptide mixture of four tumour associated antigens: preferentially expressed antigen in melanoma (PRAME), cancer/testis antigen 1 (LAGE2, NY-ESO-1), survivin (BIRC5) and Wilm's tumor protein (WT1). The cells are expanded in medium containing recombinant cytokines interleukin 6 (IL-6), 7 (IL-7), 12 (IL-12), and 15 (IL-15). Cells consist of a mixture of CD4+ and CD8+ T cells, that include effector memory (CD45RA-CD197-; on average 30%), central memory (CD45RA-CD197+; on average 43%), naïve (CD45RA+CD197+; on average 22%) and terminally-differentiated effector memory (CD45RA+CD197-; on average 5%) T cells.

Поделиться этой страницей